A Systematic Review and Statistical Analysis of Factors Influencing the Cost-Effectiveness of Transcatheter Aortic Valve Implantation for Symptomatic Severe Aortic Stenosis

Objective Transcatheter aortic valve implantation (TAVI) is a disruptive technology recommended for patients with symptomatic severe aortic stenosis (sSAS). Despite being available for over 15 years in Europe, with an extensive volume of clinical and economic evaluations across all surgical risk groups, there is little evidence on the identification of the key drivers of TAVI’s cost-effectiveness. This study sought to identify these factors and quantify their role. Methods A systematic literature review was conducted to identify published economic evaluations of TAVI. This was supplemented by health technology assessment reports. The primary outcome was the likelihood of TAVI being found cost-effective. Secondary outcomes of TAVI being dominant, and the incremental health benefits of TAVI were also explored. Results Forty-two studies, reporting 65 unique analyses, were identified. TAVI was found to be cost-effective and dominant in 74% and 20% of analyses, respectively. The latest generation balloon-expandable TAVI device (SAPIEN 3) was more likely to be found cost-effective, as was TAVI use in low-risk populations and when performed via transfemoral access route. There was heterogeneity in the approach taken to economic modelling, which may also influence estimates of cost-effectiveness. Analyses that found TAVI to be dominant always compared it to surgery and usually considered the latest generation balloon-expandable TAVI device. Largest health benefits were observed for the inoperable risk group. Conclusion For patients with sSAS, TAVI is typically a cost-effective treatment option. There are important differences by device generation, risk group and access route. It is crucial to consider these differences when appraising the health economic evidence-base for TAVI.

[1]  U. Permsuwan,et al.  Transcatheter aortic valve implantation in patients with severe symptomatic aortic valve stenosis: systematic review of cost-effectiveness analysis , 2022, The European Journal of Health Economics.

[2]  G. de Pouvourville,et al.  Cost-Effectiveness Analysis of SAPIEN 3 Transcatheter Aortic Valve Implantation Procedure Compared With Surgery in Patients With Severe Aortic Stenosis at Low Risk of Surgical Mortality in France. , 2021, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[3]  B. Prendergast,et al.  2021 ESC/EACTS Guidelines for the management of valvular heart disease. , 2021, European heart journal.

[4]  B. Prendergast,et al.  2021 ESC/EACTS Guidelines for the management of valvular heart disease. , 2021, European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery.

[5]  C. Young,et al.  Transcatheter Aortic Valve Implantation for Patients with Severe Symptomatic Aortic Stenosis , 2021, Canadian Journal of Health Technologies.

[6]  A. Keech,et al.  Transcatheter Aortic Valve Implantation (TAVI) Versus Surgical Aortic Valve Replacement for Aortic Stenosis (SAVR): A Cost-Comparison Study. , 2021, Heart, lung & circulation.

[7]  V. Lorenzoni,et al.  The cost-effectiveness of transcatheter aortic valve implantation: exploring the Italian National Health System perspective and different patient risk groups , 2021, The European Journal of Health Economics.

[8]  D. Pascual,et al.  Cost-effectiveness analysis of the SAPIEN 3 transcatheter aortic valve implant in patients with symptomatic severe aortic stenosis. , 2021, Revista espanola de cardiologia.

[9]  Astrid E. Berggreen,et al.  Impact of Anesthesia Strategy and Valve Type on Clinical Outcomes After Transcatheter Aortic Valve Replacement. , 2021, Journal of the American College of Cardiology.

[10]  M. Mack,et al.  2020 ACC/AHA Guideline for the Management of Patients With Valvular Heart Disease: Executive Summary: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. , 2020, Circulation.

[11]  M. Mack,et al.  2020 ACC/AHA Guideline for the Management of Patients With Valvular Heart Disease: Executive Summary: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. , 2020, Journal of the American College of Cardiology.

[12]  H. Thiele,et al.  Paravalvular Regurgitation According to Transcatheter Aortic Valve Prosthesis Type: Insights From the Randomized SOLVE-TAVI Trial. , 2020, JACC. Cardiovascular imaging.

[13]  D. Stub,et al.  Cost-Effectiveness of Transcatheter Versus Surgical Aortic Valve Replacement in Low-Risk Patients With Severe Aortic Stenosis. , 2020, Heart, lung & circulation.

[14]  G. Shields,et al.  Challenges in synthesising cost-effectiveness estimates , 2020, Systematic Reviews.

[15]  H. Wijeysundera,et al.  The cost-effectiveness of transcatheter aortic valve replacement in low surgical risk patients with severe aortic stenosis. , 2020, European heart journal. Quality of care & clinical outcomes.

[16]  K. Poh,et al.  Cost-Effectiveness of Transcatheter Aortic Valve Implantation in Intermediate and Low Risk Severe Aortic Stenosis Patients in Singapore. , 2020, Annals of the Academy of Medicine, Singapore.

[17]  S. Kapadia,et al.  Self-expanding intra-annular versus commercially available transcatheter heart valves in high and extreme risk patients with severe aortic stenosis (PORTICO IDE): a randomised, controlled, non-inferiority trial , 2020, The Lancet.

[18]  K. Nakao,et al.  Cost-Effectiveness of Transcatheter Aortic Valve Implantation Using a Balloon-Expandable Valve in Japan: Experience From the Japanese Pilot Health Technology Assessment. , 2020, Value in health regional issues.

[19]  I. König,et al.  Comparison of newer generation self-expandable vs. balloon-expandable valves in transcatheter aortic valve implantation: the randomized SOLVE-TAVI trial. , 2020, European heart journal.

[20]  L. Søndergaard,et al.  Cost-Effectiveness of Transcatheter versus Surgical Aortic Valve Replacement inPatients at Lower Surgical Risk: Results from the NOTION Trial. , 2019, EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.

[21]  M. Mack,et al.  Cost-Effectiveness of Transcatheter Mitral Valve Repair versus Medical Therapy in Patients with Heart Failure and Secondary Mitral Regurgitation: Results from the COAPT Trial. , 2019, Circulation.

[22]  B. Prendergast,et al.  Safety and efficacy of a self-expanding versus a balloon-expandable bioprosthesis for transcatheter aortic valve replacement in patients with symptomatic severe aortic stenosis: a randomised non-inferiority trial , 2019, The Lancet.

[23]  D. Stub,et al.  Cost-effectiveness of transcatheter aortic valve implantation compared to surgical aortic valve replacement in the intermediate surgical risk population. , 2019, International journal of cardiology.

[24]  N. Burke,et al.  A Canadian cost-effectiveness analysis of SAPIEN 3 transcatheter aortic valve implantation compared with surgery, in intermediate and high-risk severe aortic stenosis patients , 2019, ClinicoEconomics and outcomes research : CEOR.

[25]  J. Leipsic,et al.  Transcatheter Aortic‐Valve Replacement with a Balloon‐Expandable Valve in Low‐Risk Patients , 2019, The New England journal of medicine.

[26]  Andrew S. Mugglin,et al.  Transcatheter Aortic‐Valve Replacement with a Self‐Expanding Valve in Low‐Risk Patients , 2019, The New England journal of medicine.

[27]  M. Mack,et al.  Cost-Effectiveness of Transcatheter Versus Surgical Aortic Valve Replacement in Patients With Severe Aortic Stenosis at Intermediate Risk: Results From the PARTNER 2 Trial , 2019, Circulation.

[28]  G. de Pouvourville,et al.  Cost-effectiveness analysis of the SAPIEN 3 TAVI valve compared with surgery in intermediate-risk patients , 2019, Journal of medical economics.

[29]  H. Wijeysundera,et al.  Cost-Effectiveness of Self-Expandable Transcatheter Aortic Valves in Intermediate-Risk Patients. , 2018, The Annals of thoracic surgery.

[30]  B. Carabello,et al.  Aortic stenosis , 2018, Rapid Cardiac Care.

[31]  F. Petracca,et al.  Access Sites for TAVI: Patient Selection Criteria, Technical Aspects, and Outcomes , 2018, Front. Cardiovasc. Med..

[32]  P. Coyte,et al.  A cost‐utility analysis of transcatheter versus surgical aortic valve replacement for the treatment of aortic stenosis in the population with intermediate surgical risk , 2018, The Journal of thoracic and cardiovascular surgery.

[33]  N. Maniadakis,et al.  Systematic review of the cost-effectiveness of transcatheter interventions for valvular heart disease , 2018, European heart journal. Quality of care & clinical outcomes.

[34]  I. Komuro,et al.  Cost effectiveness of transcatheter aortic valve implantation in patients with aortic stenosis in Japan. , 2017, Journal of cardiology.

[35]  A. Kappetein,et al.  Cost-Effectiveness and Projected Survival of Self-Expanding Transcatheter Versus Surgical Aortic Valve Replacement for High Risk Patients in a European Setting: A Dutch Analysis Based on the CoreValve High Risk Trial , 2017 .

[36]  P. Leprince,et al.  Temporal Trends in Transcatheter Aortic Valve Replacement in France: FRANCE 2 to FRANCE TAVI. , 2017, Journal of the American College of Cardiology.

[37]  Andrew S. Mugglin,et al.  Surgical or Transcatheter Aortic‐Valve Replacement in Intermediate‐Risk Patients , 2017, The New England journal of medicine.

[38]  Sheldon Goldberg,et al.  Aortic Stenosis: Pathophysiology, Diagnosis, and Therapy. , 2017, The American journal of medicine.

[39]  M. Branny,et al.  Alternative access routes for transcatheter aortic valve implantation (TAVI) , 2017 .

[40]  M. Leon,et al.  Medical Treatment of Aortic Stenosis , 2016, Circulation.

[41]  D. Cohen,et al.  Economic Implications of Transcatheter Aortic Valve Replacement in Patients at Intermediate Surgical Risk. , 2016, Circulation.

[42]  J. Leipsic,et al.  Transcatheter aortic valve replacement versus surgical valve replacement in intermediate-risk patients: a propensity score analysis , 2016, The Lancet.

[43]  M. Mack,et al.  Transcatheter or Surgical Aortic-Valve Replacement in Intermediate-Risk Patients. , 2016, The New England journal of medicine.

[44]  D. Adams,et al.  Cost-Effectiveness of Transcatheter Aortic Valve Replacement With a Self-Expanding Prosthesis Versus Surgical Aortic Valve Replacement. , 2016, Journal of the American College of Cardiology.

[45]  M. Sculpher,et al.  Cost-utility of transcatheter aortic valve implantation for inoperable patients with severe aortic stenosis treated by medical management: a UK cost-utility analysis based on patient-level data from the ADVANCE study , 2014, Open Heart.

[46]  P. Indraratna,et al.  Systematic review of the cost-effectiveness of transcatheter aortic valve implantation. , 2014, The Journal of thoracic and cardiovascular surgery.

[47]  Peter Jüni,et al.  Predictors of permanent pacemaker implantation in patients with severe aortic stenosis undergoing TAVR: a meta-analysis. , 2014, Journal of the American College of Cardiology.

[48]  N. Moat,et al.  Is transcatheter aortic valve implantation (TAVI) a cost-effective treatment in patients who are ineligible for surgical aortic valve replacement? A systematic review of economic evaluations , 2014, Journal of medical economics.

[49]  S. Bayliss,et al.  Cost-effectiveness of transcatheter aortic valve implantation (TAVI) for aortic stenosis in patients who are high risk or contraindicated for surgery: a model-based economic evaluation. , 2013, Health technology assessment.

[50]  R. Goeree,et al.  Cost-effectiveness of the Edwards SAPIEN transcatheter heart valve compared with standard management and surgical aortic valve replacement in patients with severe symptomatic aortic stenosis: a Canadian perspective. , 2013, The Journal of thoracic and cardiovascular surgery.

[51]  D. Owens,et al.  Transcatheter Aortic Valve Replacement in Nonsurgical Candidates With Severe, Symptomatic Aortic Stenosis: A Cost-Effectiveness Analysis , 2013, Circulation. Cardiovascular quality and outcomes.

[52]  S. Plein,et al.  The cost-effectiveness of transcatheter aortic valve implantation versus surgical aortic valve replacement in patients with severe aortic stenosis at high operative risk , 2013, Heart.

[53]  J. Webb,et al.  Cost effectiveness of transcatheter aortic valve replacement compared to medical management in inoperable patients with severe aortic stenosis: Canadian analysis based on the PARTNER Trial Cohort B findings , 2013, Journal of medical economics.

[54]  W. Toff,et al.  TRANSCATHETER AORTIC VALVE IMPLANTATION FOR SEVERE AORTIC STENOSIS: THE COST-EFFECTIVENESS CASE FOR INOPERABLE PATIENTS IN THE UNITED KINGDOM , 2013, International Journal of Technology Assessment in Health Care.

[55]  M. Mack,et al.  Cost-effectiveness of transcatheter aortic valve replacement compared with surgical aortic valve replacement in high-risk patients with severe aortic stenosis: results of the PARTNER (Placement of Aortic Transcatheter Valves) trial (Cohort A). , 2012, Journal of the American College of Cardiology.

[56]  M. Dweck,et al.  Calcific aortic stenosis: a disease of the valve and the myocardium. , 2012, Journal of the American College of Cardiology.

[57]  Jennifer Taylor,et al.  ESC/EACTS Guidelines on the management of valvular heart disease. , 2012, European heart journal.

[58]  Alain Cribier,et al.  Transcatheter aortic valve implantation 10-year anniversary: review of current evidence and clinical implications. , 2012, European heart journal.

[59]  E. Tuzcu,et al.  Markov model for selection of aortic valve replacement versus transcatheter aortic valve implantation (without replacement) in high-risk patients. , 2012, The American journal of cardiology.

[60]  T. Marwick,et al.  Perspective on the cost-effectiveness of transapical aortic valve implantation in high-risk patients: Outcomes of a decision-analytic model. , 2012, Annals of cardiothoracic surgery.

[61]  Alain Cribier,et al.  Development of transcatheter aortic valve implantation (TAVI): a 20-year odyssey. , 2012, Archives of cardiovascular diseases.

[62]  W. O’Neill,et al.  Cost-Effectiveness of Transcatheter Aortic Valve Replacement Compared With Standard Care Among Inoperable Patients With Severe Aortic Stenosis: Results From the Placement of Aortic Transcatheter Valves (PARTNER) Trial (Cohort B) , 2012, Circulation.

[63]  S. Palmer,et al.  Cost-effectiveness of transcatheter aortic valve replacement in patients ineligible for conventional aortic valve replacement , 2011, Heart.

[64]  E. Bates Treatment Options in Severe Aortic Stenosis , 2011, Circulation.

[65]  Stuart J Pocock,et al.  Transcatheter versus surgical aortic-valve replacement in high-risk patients. , 2011, The New England journal of medicine.

[66]  S. Pocock,et al.  Transcatheter aortic-valve implantation for aortic stenosis in patients who cannot undergo surgery. , 2010, The New England journal of medicine.

[67]  M. Forsting,et al.  Silent and Apparent Cerebral Ischemia After Percutaneous Transfemoral Aortic Valve Implantation: A Diffusion-Weighted Magnetic Resonance Imaging Study , 2010, Circulation.

[68]  Eric R. Ziegel,et al.  The Elements of Statistical Learning , 2003, Technometrics.

[69]  Assaf Bash,et al.  Percutaneous Transcatheter Implantation of an Aortic Valve Prosthesis for Calcific Aortic Stenosis: First Human Case Description , 2002, Circulation.

[70]  O. Hess,et al.  Spontaneous course of aortic valve disease. , 1987, European heart journal.

[71]  Franz Schwarz,et al.  The Effect of Aortic Valve Replacement on Survival , 1982, Circulation.

[72]  Transcatheter aortic valve implantation (TAVI) for the treatment of patients with severe symptomatic aortic stenosis at intermediate surgical risk , 2019 .

[73]  N. Sikich,et al.  Transcatheter Aortic Valve Implantation for Treatment of Aortic Valve Stenosis: A Health Technology Assessment. , 2016, Ontario health technology assessment series.

[74]  C. Roobottom,et al.  Transcatheter aortic valve insertion (TAVI): a review. , 2014, The British journal of radiology.

[75]  B. Ramlawi,et al.  Surgical Approaches to Aortic Valve Replacement and Repair-Insights and Challenges. , 2014, Interventional cardiology.

[76]  R. Goeree,et al.  Transcatheter aortic valve implantation (TAVI) for treatment of aortic valve stenosis: an evidence-based Analysis (part B). , 2012, Ontario health technology assessment series.

[77]  M. Mack,et al.  Transapical minimally invasive aortic valve implantation , 2007 .